Caroline M. Robb

ORCID: 0000-0002-9126-1307
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer-related Molecular Pathways
  • Income, Poverty, and Inequality
  • Poverty, Education, and Child Welfare
  • Advanced Breast Cancer Therapies
  • Colorectal Cancer Treatments and Studies
  • Microtubule and mitosis dynamics
  • Calcium signaling and nucleotide metabolism
  • Cell death mechanisms and regulation
  • PARP inhibition in cancer therapy
  • Ubiquitin and proteasome pathways
  • Cancer therapeutics and mechanisms
  • Human Rights and Development
  • Child Nutrition and Water Access
  • International Development and Aid
  • Synthesis and biological activity
  • Canadian Identity and History
  • Cancer, Hypoxia, and Metabolism
  • Cancer-related gene regulation
  • Social Policy and Reform Studies
  • Cancer Genomics and Diagnostics
  • NF-κB Signaling Pathways
  • PI3K/AKT/mTOR signaling in cancer
  • Vitamin C and Antioxidants Research
  • Lung Cancer Treatments and Mutations
  • Sirtuins and Resveratrol in Medicine

University of Nebraska Medical Center
2015-2020

Nebraska Medical Center
2017-2020

University of Kansas
2014

University of Colorado Denver
2012

University of Colorado Cancer Center
2012

International Monetary Fund
2003

In this manuscript, for the first time, we report synthesis of a PROTAC that selectively degrades cyclin dependent kinase 9 (CDK9).

10.1039/c7cc03879h article EN Chemical Communications 2017-01-01

Colorectal cancer (CRC) remains one of the leading causes related deaths in United States. Currently, there are limited therapeutic options for patients suffering from CRC, none which focus on cell signaling mechanisms controlled by popular kinase family, cyclin dependent kinases (CDKs). Here we evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent 5 (CDK5) neurodegenerative disorders. CDK5 has been implicated number cancers, most recently as an oncogene colorectal...

10.18632/oncotarget.23749 article EN Oncotarget 2017-12-28

Aid, by its very definition, is a manifestation of inequality. Could aid then be improved recognizing various forms inequality, including the unequal distribution power? Being poor usually means being powerless; but aid system dominated interests powerful, as opposed to the powerless. Aid has historically been influenced political processes, world economic environment, commercial and interests, well success or failure poverty reduction initiatives. But change within this system not been...

10.4324/9781849771702-11 article EN 2013-06-17

Developing small molecules that indirectly regulate Mcl-1 function has attracted a lot of attention in recent years. Here, we report the discovery an aminopyrazole, 2-([1,1′-biphenyl]-4-yl)-<i>N</i>-(5-cyclobutyl-1<i>H</i>-pyrazol-3-yl)acetamide (analog 24), which selectively inhibited cyclin-dependent kinase (CDK) 5 over CDK2 cancer cell lines. We also show analog 24 reduced levels concentration-dependent manner Using panel doxycycline inducible lines, CDK5 inhibitor modulates while CDK4/6...

10.1124/mol.119.116855 article EN cc-by-nc Molecular Pharmacology 2019-08-29

Ewing sarcoma is a malignant bone cancer that primarily occurs in children and adolescents. Eighty-five percent of characterized by the presence aberrant chimeric EWS/FLI1 fusion gene. Previously, we demonstrated an interaction between wild-type EWS led to inhibition activity mitotic dysfunction. Although defective mitosis considered be critical step initiation, it unknown how interference with contributes formation. Here, demonstrate EWS/FLI1- EWS-knockdown cells display high incidence...

10.4161/cc.29337 article EN Cell Cycle 2014-06-19

The release of an active drug from the prodrug generates a pro-fragment that typically has no biological activity and could result in adverse effects. By combining two drugs, wherein each acts as other will eliminate prodrug. As they are prodrugs symbiotic, we termed these symbiotic (SymProDs). To test this idea, generated SymProDs using NFκB inhibitors contain reactive α-methylene-γ-butyrolactone moiety CDK with solvent exposed secondary nitrogen atoms. We show amine containing undergo slow...

10.1111/cbdd.13684 article EN Chemical Biology & Drug Design 2020-04-01

e18512 Background: MultipleBCL-2 and PARP inhibitors are currently in clinical trials, or have been approved for use, hematological malignancies solid tumors. Venetoclax, an inhibitor of the apoptosis regulator B-cell lymphoma-2 (BCL-2), has activity patients with chronic lymphocytic leukemia (CLL) acute myeloid (AML). inhibitors, such as Olaparib, exploit synthetic lethality homologous recombination-deficient tumors, notably breast ovarian cancers. However, treated BCL-2 often face relapse...

10.1200/jco.2024.42.16_suppl.e18512 article EN Journal of Clinical Oncology 2024-06-01

The objective of this paper is to present some early experiences poverty and social impact analysis (PSIA) from the PRGF-supported programs in African Department. illustrates that many staff country reports have taken a first step toward PSIA by making more explicit links between policies. Various examples highlight even though relationships can be complex analysis, as result, may not definitive, it possible assess potential effects countries with limited data, therefore contribute informed...

10.2139/ssrn.879118 article EN SSRN Electronic Journal 2003-01-01

The views expressed in this Working Paper are those of the author(s) and do not necessarily represent IMF or policy.Working Papers describe research progress by published to eJicit comments further debate.The objective paper is present some early experiences poverty social impact analysis (PSIA) from PRGF-supported prograrus African Department.The illustrates that many staff country reports have taken a first step toward PSIA making more explicit links between policies.Various examples...

10.5089/9781451846348.001 article EN IMF Working Paper 2003-01-01

Abstract Purpose: To investigate the role of CDK5 in Colorectal Cancer. Background: Cancer (CRC) is fourth most commonly diagnosed form cancer and second leading cause related deaths United States. Most CRC are due to metastatic disease, making identification targets important for development therapeutics. Materials Methods: Gene expression analysis was performed comparing primary tumors from orthotopic model. Primary colon corresponding liver an model human tissue were analyzed using...

10.1158/1538-7445.am2015-3088 article EN Cancer Research 2015-08-01

e21018 Background: Monoclonal antibodies against Epidermal Growth Factor Receptor (EGFR) demonstrated efficacy in mCRC patients without mutations the KRAS gene. Previous data breast and lung cancer suggested that MYC GCN affects sensitivity to anti-EGFR agents. Methods: This retrospective study was conducted a cohort of 303 treated with cetuximab/panitumumab, either alone (N=24) or combination chemotherapy (N=279). assessed by fluorescence situ hybridization (FISH) primary colorectal tissue...

10.1200/jco.2012.30.15_suppl.e21018 article EN Journal of Clinical Oncology 2012-05-20
Coming Soon ...